secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161170
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine reports positive Phase 2 data for bitopertin in EPP and updates for DISC-0974 and DISC-3405 at EHA 2024
--------------------------------------------------------------------------------

- Bitopertin reduced protoporphyrin IX by 40% in 60 mg group and cut phototoxic reactions by 75.3% (p=0.011) in AURORA trial.
- DISC-0974 showed 68.9% of non-transfusion dependent myelofibrosis patients had hemoglobin response ≥1.5 g/dL; one TD patient became transfusion independent.
- DISC-3405 demonstrated >50% mean serum iron reduction sustained for at least 4 weeks at 300 mg dose in healthy volunteers.
- No serious adverse events reported across all three programs to date.
- Data were presented at European Hematology Association 2024 Congress on June 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524161170/0001193125-24-161170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524161170/d826950d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer